tradingkey.logo

Glaukos Corp

GKOS
View Detailed Chart

83.470USD

-2.370-2.76%
Close 09/19, 16:00ETQuotes delayed by 15 min
4.78BMarket Cap
LossP/E TTM

Glaukos Corp

83.470

-2.370-2.76%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.76%

5 Days

+0.86%

1 Month

-8.30%

6 Months

-17.55%

Year to Date

-44.33%

1 Year

-35.83%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
50 / 207
Overall Ranking
125 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 15 analysts
Buy
Current Rating
123.500
Target Price
+43.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.57% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 47.56.
Fairly Valued
The company’s latest PE is -51.61, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 61.06M shares, increasing 0.03% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 6.10M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Ticker SymbolGKOS
CompanyGlaukos Corp
CEOMr. Thomas William Burns
Websitehttps://www.glaukos.com
KeyAI